OPKO Health, Inc. (LON:0KCS)

London flag London · Delayed Price · Currency is GBP · Price in USD
1.335
-0.026 (-1.88%)
Dec 16, 2025, 4:18 PM BST
-16.04%
Market Cap774.45M
Revenue (ttm)477.66M
Net Income (ttm)-134.20M
Shares Outn/a
EPS (ttm)-0.18
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,086
Average Volume5,897
Open1.360
Previous Close1.361
Day's Range1.335 - 1.369
52-Week Range1.130 - 2.020
Betan/a
RSI51.85
Earnings DateFeb 27, 2026

About OPKO Health

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company’s Diagnostics segment operates BioReference Laboratories that offer laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women’s health, and correctional healthcare to physician offices, clinics, hospitals, employers, ... [Read more]

Industry Medical - Pharmaceuticals
Sector Healthcare
Founded 2007
Employees 2,997
Stock Exchange London Stock Exchange
Ticker Symbol 0KCS
Full Company Profile

Financial Performance

In 2024, OPKO Health's revenue was $713.14 million, a decrease of -17.41% compared to the previous year's $863.50 million. Losses were -$53.22 million, -71.82% less than in 2023.

Financial numbers in USD Financial Statements

News

Here's Why You Should Retain OPKO Health Stock in Your Portfolio Now

OPK leans on RAYALDEE momentum and strategic partnerships as pipeline trials advance, though reliance on its lone U.S. drug adds risk.

7 days ago - Nasdaq

Friday 11/21 Insider Buying Report: GLOO, OPK

As the saying goes, there are many possible reasons for an insider to sell a stock, but only one reason to buy -- they expect to make money. So let's look at two noteworthy recent insider buys. At GLO...

25 days ago - Nasdaq

JP Morgan Initiates Coverage on OPKO Health with Neutral Rating | OPK Stock News

JP Morgan Initiates Coverage on OPKO Health with Neutral Rating | OPK Stock News

26 days ago - GuruFocus

OPKO Health to Participate in the Piper Sandler 37th Annual Healthcare Conference

MIAMI, Nov. 19, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq: OPK) announced today that management will be participating in the Piper Sandler 37th Annual Healthcare Conference, being held Decemb...

26 days ago - GlobeNewsWire

OPKO Health Inc (OPK) Q3 2025 Earnings Call Highlights: Strategic Moves and Financial Performance

OPKO Health Inc (OPK) Q3 2025 Earnings Call Highlights: Strategic Moves and Financial Performance

6 weeks ago - GuruFocus

Q3 2025 OPKO Health Inc Earnings Call Transcript

Q3 2025 OPKO Health Inc Earnings Call Transcript

6 weeks ago - GuruFocus

OPK Q3 Earnings Beat Estimates, Sales Miss, Gross Margin Expands

OPKO Health's Q3 earnings top estimates despite lower sales. Cost cuts and product strength boost margins and operating income.

6 weeks ago - Nasdaq

OPK: Barrington Research Maintains Outperform Rating with $2.25 Price Target | OPK Stock News

OPK: Barrington Research Maintains Outperform Rating with $2.25 Price Target | OPK Stock News

6 weeks ago - GuruFocus

Decoding OPKO Health Inc (OPK): A Strategic SWOT Insight

Decoding OPKO Health Inc (OPK): A Strategic SWOT Insight

6 weeks ago - GuruFocus

Compared to Estimates, OPKO Health (OPK) Q3 Earnings: A Look at Key Metrics

While the top- and bottom-line numbers for OPKO Health (OPK) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics co...

6 weeks ago - Nasdaq

OPK Reports Decline in Q3 Revenue but Sees Boost in Operating Income

OPK Reports Decline in Q3 Revenue but Sees Boost in Operating Income

6 weeks ago - GuruFocus

OPKO Health Inc Reports Q3 2025 Earnings: EPS of $0.03 Beats Estimates, Revenue of $151. ...

OPKO Health Inc Reports Q3 2025 Earnings: EPS of $0.03 Beats Estimates, Revenue of $151.7 Million Misses Expectations

6 weeks ago - GuruFocus

OPKO Health Reports Third Quarter 2025 Business Highlights and Financial Results

MIAMI, Oct. 29, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (OPKO) reports business highlights and financial results for the three and nine months ended September 30, 2025. Highlights fro...

6 weeks ago - GlobeNewsWire

OPK Collaborates with Regeneron to Develop Multispecific Antibodies

OPK Collaborates with Regeneron to Develop Multispecific Antibodies

6 weeks ago - GuruFocus

OPKO Health Q3 Earnings Preview

6 weeks ago - Seeking Alpha

Here's Why You Should Add OPKO Health Stock to Your Portfolio

OPK benefits from RAYALDEE momentum, strategic deals and advancing trials amid stiff competition and dependence risks.

7 weeks ago - Nasdaq

OPKO Health to Report Third Quarter 2025 Financial Results on October 29

MIAMI, Oct. 22, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three and nine months ended September 30, 2025 after the close of the U...

7 weeks ago - GlobeNewsWire

Opko Health (OPK) Q2 Revenue Falls 14%

4 months ago - The Motley Fool

OPKO Health (OPK) Advances Strategic Initiatives with Key Asset Sale

OPKO Health (OPK) Advances Strategic Initiatives with Key Asset Sale

4 months ago - GuruFocus

OPKO Health Reports Second Quarter 2025 Business Highlights and Financial Results

MIAMI, July 31, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and six months ended June 30, 2025. Highlights from the second ...

4 months ago - GlobeNewsWire